Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP5 | P51878 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625264 | 0.90 | CYP2D6 (0.55) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL428016 | 0.88 | CHKA (0.52) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL10104420 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL24565989 | 0.87 | ALDH1A1 (0.54) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL13960087 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL24362682 | 0.86 | TSHR (0.51) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL16731644 | 0.84 | CXCR3 (0.48) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL24815470 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 | |
| SCHEMBL24362674 | 0.84 | CYP2D6 (0.49) | ALDH1A1KDM4ECYP2D6CYP3A4TSHR | |
| SCHEMBL21951132 | 0.83 | HIF1A (0.56) | ALDH1A1KDM4EMAPTCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-4001267-A1 | FUSED RING PYRIMIDINE AMINO COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2022-05-25 | — | — | EP | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | ALDH1A1 3221/4885KDM4E 1104/4885MAPT 3474/4885 |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | DDR2, DDR1, DOCK2 | ALDH1A1 3898/4885KDM4E 2368/4885MAPT 2707/4885 |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | FLT3, ABL1, MCL1 | ALDH1A1 3264/4885KDM4E 1481/4885MAPT 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.